In this real-world setting analysis, ICI PFS in EGFR-mutated, ALK- or ROS1-translocated NSCLC patients appeared close to that observed in pretreated unselected NSCLC patients in randomized-controlled trials or observational studies. The gene discussed is ALK; the disease is non-small cell lung carcinoma.